Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The recent launch event of the Experimental Medicine Industry Partnership was an exciting collaboration between industry representatives and researchers from the University of Oxford. During the event, a series of workshops were held to discuss opportunities, challenges, and future directions for the application of experimental medicine in psychiatric drug development.

Business Unity and connection partnership as ropes shaped as a circle in a group of diverse strings connected together shaped as a support symbol expressing the feeling of teamwork and togetherness.

Dr Susannah Murphy, Department of Psychiatry, University of Oxford, explains:

 

'The Experimental Medicine Industry Partnership (EMIP) is a fantastic opportunity for industry partners and researchers to work together to share expertise and maximise opportunities for developing improved psychiatric treatments. By offering tailored peer review and advice the EMIP will help to rapidly progress new treatments into clinical trials, bringing potential new, life changing treatments a step closer to improving the lives of patients.'

Professor Catherine Harmer, Department of Psychiatry, University of Oxford, said:

 

'It was fascinating to hear pressing questions from an industry perspective and to take part in discussions with other academics. The conversations have spearheaded many collaborations and have inspired us to develop our models in ways that can also work for industry and their requirements. I look forward to continued and future collaborations.'

50 representatives from 15 industry partners and 90 Oxford researchers with expertise in cognitive neuroscience, pharmacology treatment, lifestyle interventions, gut health and precision psychiatry, took part in the AIMday event in July 2021, . 

Read more about this and other topics discussed during the event

For more information about the Experimental Medicine and Industry Partnership (EMIP) 

An Academic Industry Meeting Day (AIMday) is an innovative networking event that allows organisations external to the University of Oxford to set the agenda and gain academic perspective on industry challenges. 

The event was developed through the National Institute for Health Research Oxford Health Biomedical Research Centre (a partnership between the University of Oxford and the Oxford Health NHS Foundation Trust).

Similar stories

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

IDRM officially opens in Oxford

A celebration for the opening of the Institute of Developmental & Regenerative Medicine (IDRM) led by Paul Riley took place on Tuesday 12 July 2022, attended by many DPAG members who have recently relocated to this fantastic new Institute.

NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills

Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be offered an app-based treatment programme instead, NICE has said.

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from researchers at the Department of Paediatrics and the Nuffield Department of Clinical Neurosciences has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.